Key result
Prolonged muscle weakness following discontinuation of ND-NMBAs and corticosteroids was attributed to pathology at both the neuromuscular junction and muscle.
Why the study?
Does long-term use of nondepolarizing neuromuscular blocking agents and corticosteroids cause prolonged muscle weakness in patients with acute respiratory insufficiency?
Case Report (n=3)
Does long-term use of nondepolarizing neuromuscular blocking agents and corticosteroids cause prolonged muscle weakness in patients with acute respiratory insufficiency?
Prolonged paralysis after ND-NMBA use in critically ill patients is likely multifactorial, involving both neuromuscular junction and muscle pathology exacerbated by corticosteroids, hepatic dysfunction, and acidosis.
No takes yet. Share an insight, caveat, or question.
Clinicians should monitor for prolonged weakness after ND-NMBAs in hepatic impairment; leaves open predisposing factors and lesion site.
Barohn et al. (1994) conducted a case report in Acute respiratory insufficiency with prolonged muscle weakness (n=3). Nondepolarizing neuromuscular blocking agents (ND-NMBA) and corticosteroids was evaluated on Prolonged muscle weakness. Prolonged muscle weakness following discontinuation of ND-NMBAs and corticosteroids was attributed to pathology at both the neuromuscular junction and muscle.